Pharming receives positive CHMP opinion for Joenja to treat rare primary immunodeficiency
Pharming Group (NASDAQ:PHAR), a global biopharmaceutical company dedicated to transforming the lives of patients with rare diseases, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion.


_1369156_640x360_2493942339576-640x360.webp&w=3840&q=75)

_1369105_640x360_2493916739746-640x360.webp&w=3840&q=75)
_1369093_640x360_2493917763763-640x360.webp&w=3840&q=75)


_1369071_640x360_2493911107942-640x360.webp&w=3840&q=75)


_1368988_640x360_2493952067662-640x360.webp&w=3840&q=75)